Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study to Evaluate the Efficacy and Safety of Camizestrant Plus Ribociclib in Patients With Hormone Receptor Positive (HR+) Breast Cancer

NCT07195227 is registered in ClinicalTrials.gov with MedSIR as lead sponsor.

NCT NCT07195227
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07195227 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study to Evaluate the Efficacy and Safety of Camizestrant Plus Ribociclib in Patients With Hormone Receptor Positive (HR+) Breast Cancer
Lead sponsor
MedSIR
Phase
Phase 2
Overall status
Recruiting
Start date
March 24, 2026
Completion date
March 31, 2028
Enrollment
150 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, hormon receptor positive breast cancer